![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RAB11A |
Gene summary for RAB11A |
![]() |
Gene information | Species | Human | Gene symbol | RAB11A | Gene ID | 8766 |
Gene name | RAB11A, member RAS oncogene family | |
Gene Alias | YL8 | |
Cytomap | 15q22.31 | |
Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | P62491 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8766 | RAB11A | CA_HPV_1 | Human | Cervix | CC | 4.39e-05 | -1.31e-01 | 0.0264 |
8766 | RAB11A | N_HPV_1 | Human | Cervix | N_HPV | 2.49e-03 | -9.69e-02 | 0.0079 |
8766 | RAB11A | CCI_2 | Human | Cervix | CC | 7.53e-06 | 1.07e+00 | 0.5249 |
8766 | RAB11A | Tumor | Human | Cervix | CC | 2.58e-14 | 4.78e-01 | 0.1241 |
8766 | RAB11A | sample3 | Human | Cervix | CC | 3.38e-22 | 5.28e-01 | 0.1387 |
8766 | RAB11A | T3 | Human | Cervix | CC | 4.64e-22 | 5.65e-01 | 0.1389 |
8766 | RAB11A | HTA11_347_2000001011 | Human | Colorectum | AD | 2.28e-07 | 4.38e-01 | -0.1954 |
8766 | RAB11A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.81e-03 | -1.98e-01 | 0.3005 |
8766 | RAB11A | A001-C-207 | Human | Colorectum | FAP | 1.35e-02 | -2.57e-01 | 0.1278 |
8766 | RAB11A | A015-C-203 | Human | Colorectum | FAP | 1.47e-16 | -3.05e-01 | -0.1294 |
8766 | RAB11A | A015-C-204 | Human | Colorectum | FAP | 3.09e-04 | -3.03e-01 | -0.0228 |
8766 | RAB11A | A002-C-201 | Human | Colorectum | FAP | 1.01e-09 | -3.26e-01 | 0.0324 |
8766 | RAB11A | A001-C-119 | Human | Colorectum | FAP | 1.50e-02 | -2.73e-01 | -0.1557 |
8766 | RAB11A | A001-C-108 | Human | Colorectum | FAP | 7.54e-15 | -3.29e-01 | -0.0272 |
8766 | RAB11A | A002-C-205 | Human | Colorectum | FAP | 9.06e-12 | -3.37e-01 | -0.1236 |
8766 | RAB11A | A001-C-104 | Human | Colorectum | FAP | 9.80e-06 | -2.65e-01 | 0.0184 |
8766 | RAB11A | A015-C-005 | Human | Colorectum | FAP | 3.18e-03 | -2.73e-01 | -0.0336 |
8766 | RAB11A | A015-C-006 | Human | Colorectum | FAP | 3.16e-09 | -4.14e-01 | -0.0994 |
8766 | RAB11A | A015-C-106 | Human | Colorectum | FAP | 2.86e-10 | -2.94e-01 | -0.0511 |
8766 | RAB11A | A002-C-114 | Human | Colorectum | FAP | 1.75e-11 | -3.97e-01 | -0.1561 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003246511 | Thyroid | ATC | regulation of cytokinesis | 47/6293 | 92/18723 | 3.95e-04 | 2.39e-03 | 47 |
GO:190274911 | Thyroid | ATC | regulation of cell cycle G2/M phase transition | 51/6293 | 102/18723 | 4.45e-04 | 2.64e-03 | 51 |
GO:190307824 | Thyroid | ATC | positive regulation of protein localization to plasma membrane | 34/6293 | 62/18723 | 4.66e-04 | 2.74e-03 | 34 |
GO:190198914 | Thyroid | ATC | positive regulation of cell cycle phase transition | 56/6293 | 115/18723 | 5.63e-04 | 3.25e-03 | 56 |
GO:009724221 | Thyroid | ATC | amyloid-beta clearance | 23/6293 | 38/18723 | 6.05e-04 | 3.44e-03 | 23 |
GO:00513027 | Thyroid | ATC | regulation of cell division | 80/6293 | 177/18723 | 8.54e-04 | 4.68e-03 | 80 |
GO:190199213 | Thyroid | ATC | positive regulation of mitotic cell cycle phase transition | 46/6293 | 93/18723 | 1.11e-03 | 5.85e-03 | 46 |
GO:004505621 | Thyroid | ATC | transcytosis | 14/6293 | 21/18723 | 1.99e-03 | 9.54e-03 | 14 |
GO:003030719 | Thyroid | ATC | positive regulation of cell growth | 74/6293 | 166/18723 | 2.06e-03 | 9.73e-03 | 74 |
GO:004863815 | Thyroid | ATC | regulation of developmental growth | 136/6293 | 330/18723 | 2.17e-03 | 1.02e-02 | 136 |
GO:003095312 | Thyroid | ATC | astral microtubule organization | 8/6293 | 10/18723 | 3.60e-03 | 1.58e-02 | 8 |
GO:004592720 | Thyroid | ATC | positive regulation of growth | 106/6293 | 259/18723 | 7.90e-03 | 3.06e-02 | 106 |
GO:190241414 | Thyroid | ATC | protein localization to cell junction | 43/6293 | 94/18723 | 9.54e-03 | 3.50e-02 | 43 |
GO:00330595 | Thyroid | ATC | cellular pigmentation | 26/6293 | 53/18723 | 1.42e-02 | 4.91e-02 | 26 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0516414 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0516415 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0516441 | Cervix | N_HPV | Influenza A | 16/349 | 171/8465 | 1.81e-03 | 1.12e-02 | 8.75e-03 | 16 |
hsa0516451 | Cervix | N_HPV | Influenza A | 16/349 | 171/8465 | 1.81e-03 | 1.12e-02 | 8.75e-03 | 16 |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa04961 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa04972 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa049611 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa049721 | Colorectum | AD | Pancreatic secretion | 36/2092 | 102/8465 | 1.06e-02 | 3.98e-02 | 2.54e-02 | 36 |
hsa049724 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa049725 | Colorectum | MSS | Pancreatic secretion | 33/1875 | 102/8465 | 1.09e-02 | 3.75e-02 | 2.30e-02 | 33 |
hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa049726 | Colorectum | FAP | Pancreatic secretion | 34/1404 | 102/8465 | 2.43e-05 | 2.78e-04 | 1.69e-04 | 34 |
hsa049616 | Colorectum | FAP | Endocrine and other factor-regulated calcium reabsorption | 18/1404 | 53/8465 | 1.52e-03 | 7.94e-03 | 4.83e-03 | 18 |
hsa041447 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa049727 | Colorectum | FAP | Pancreatic secretion | 34/1404 | 102/8465 | 2.43e-05 | 2.78e-04 | 1.69e-04 | 34 |
hsa049617 | Colorectum | FAP | Endocrine and other factor-regulated calcium reabsorption | 18/1404 | 53/8465 | 1.52e-03 | 7.94e-03 | 4.83e-03 | 18 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAB11A | SNV | Missense_Mutation | novel | c.189G>C | p.Gln63His | p.Q63H | P62491 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RAB11A | SNV | Missense_Mutation | c.31C>T | p.Leu11Phe | p.L11F | P62491 | protein_coding | deleterious_low_confidence(0.01) | benign(0.105) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD | |
RAB11A | SNV | Missense_Mutation | rs759435629 | c.521N>A | p.Arg174His | p.R174H | P62491 | protein_coding | tolerated_low_confidence(0.31) | benign(0.001) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
RAB11A | SNV | Missense_Mutation | novel | c.158N>C | p.Ile53Thr | p.I53T | P62491 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.519) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
RAB11A | SNV | Missense_Mutation | novel | c.382N>G | p.Leu128Val | p.L128V | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.822) | TCGA-AG-3887-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | irinotecan | SD |
RAB11A | SNV | Missense_Mutation | novel | c.86C>A | p.Ser29Tyr | p.S29Y | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.711) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAB11A | SNV | Missense_Mutation | novel | c.461N>T | p.Ser154Leu | p.S154L | P62491 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.994) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAB11A | SNV | Missense_Mutation | novel | c.221G>A | p.Arg74Gln | p.R74Q | P62491 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.827) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
RAB11A | SNV | Missense_Mutation | c.386G>A | p.Arg129His | p.R129H | P62491 | protein_coding | deleterious_low_confidence(0.02) | benign(0.025) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
RAB11A | SNV | Missense_Mutation | novel | c.70N>C | p.Lys24Gln | p.K24Q | P62491 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |